These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 39258426)

  • 1. Targeting the CLK2/SRSF9 splicing axis in prostate cancer leads to decreased ARV7 expression.
    Van Goubergen J; Peřina M; Handle F; Morales E; Kremer A; Schmidt O; Kristiansen G; Cronauer MV; Santer FR
    Mol Oncol; 2024 Sep; ():. PubMed ID: 39258426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel inhibitor of ARfl and ARv7 induces protein degradation to overcome enzalutamide resistance in advanced prostate cancer.
    Li Y; Chu Y; Shi G; Wang X; Ye W; Shan C; Wang D; Zhang D; He W; Jiang J; Ma S; Han Y; Zhao Z; Du S; Chen Z; Li Z; Yang Y; Wang C; Xu X; Wu H
    Acta Pharm Sin B; 2022 Nov; 12(11):4165-4179. PubMed ID: 36386477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen Receptor and Its Splicing Variant 7 Expression in Peripheral Blood Mononuclear Cells and in Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer.
    Marín-Aguilera M; Jiménez N; Reig Ò; Montalbo R; Verma AK; Castellano G; Mengual L; Victoria I; Pereira MV; Milà-Guasch M; García-Recio S; Benítez-Ribas D; Cabezón R; González A; Juan M; Prat A; Mellado B
    Cells; 2020 Jan; 9(1):. PubMed ID: 31947623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased chromatin accessibility mediated by nuclear factor I drives transition to androgen receptor splice variant dependence in castration-resistant prostate cancer.
    Poluben L; Nouri M; Liang J; Varkaris A; Ersoy-Fazlioglu B; Voznesensky O; Lee II; Qiu X; Cato L; Seo JH; Freedman ML; Sowalsky AG; Lack NA; Corey E; Nelson PS; Brown M; Long HW; Russo JW; Balk SP
    bioRxiv; 2024 Jun; ():. PubMed ID: 38260576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-LAK cell-originated protein kinase (TOPK) enhances androgen receptor splice variant (ARv7) and drives androgen-independent growth in prostate cancer.
    Alhawas L; Amin KS; Salla B; Banerjee PP
    Carcinogenesis; 2021 Apr; 42(3):423-435. PubMed ID: 33185682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer.
    Moses MA; Kim YS; Rivera-Marquez GM; Oshima N; Watson MJ; Beebe KE; Wells C; Lee S; Zuehlke AD; Shao H; Bingman WE; Kumar V; Malhotra SV; Weigel NL; Gestwicki JE; Trepel JB; Neckers LM
    Cancer Res; 2018 Jul; 78(14):4022-4035. PubMed ID: 29764864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer.
    Cato L; de Tribolet-Hardy J; Lee I; Rottenberg JT; Coleman I; Melchers D; Houtman R; Xiao T; Li W; Uo T; Sun S; Kuznik NC; Göppert B; Ozgun F; van Royen ME; Houtsmuller AB; Vadhi R; Rao PK; Li L; Balk SP; Den RB; Trock BJ; Karnes RJ; Jenkins RB; Klein EA; Davicioni E; Gruhl FJ; Long HW; Liu XS; Cato ACB; Lack NA; Nelson PS; Plymate SR; Groner AC; Brown M
    Cancer Cell; 2019 Mar; 35(3):401-413.e6. PubMed ID: 30773341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptor splice variant 7 functions independently of the full length receptor in prostate cancer cells.
    Liang J; Wang L; Poluben L; Nouri M; Arai S; Xie L; Voznesensky OS; Cato L; Yuan X; Russo JW; Long HW; Brown M; Chen S; Balk SP
    Cancer Lett; 2021 Oct; 519():172-184. PubMed ID: 34256096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7).
    Lin SJ; Chou FJ; Li L; Lin CY; Yeh S; Chang C
    Cancer Lett; 2017 Jul; 398():62-69. PubMed ID: 28373004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The miR-361-3p increases enzalutamide (Enz) sensitivity via targeting the ARv7 and MKNK2 to better suppress the Enz-resistant prostate cancer.
    Liu B; Sun Y; Tang M; Liang C; Huang CP; Niu Y; Wang Z; Chang C
    Cell Death Dis; 2020 Sep; 11(9):807. PubMed ID: 32978369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of AR/ARV7 Expression in Isolated Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer (SAKK 08/14 IMPROVE Trial).
    Hench IB; Cathomas R; Costa L; Fischer N; Gillessen S; Hench J; Hermanns T; Kremer E; Mingrone W; Mestre RP; Püschel H; Rothermundt C; Ruiz C; Tolnay M; Burg PV; Bubendorf L; Vlajnic T; Sakk SGFCCR
    Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31374981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer.
    Chou FJ; Lin C; Tian H; Lin W; You B; Lu J; Sahasrabudhe D; Huang CP; Yang V; Yeh S; Niu Y; Chang C
    Cell Death Dis; 2020 Nov; 11(11):942. PubMed ID: 33139720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen Receptor Splice Variants Are Not Substrates of Nonsense-Mediated Decay.
    Ajiboye AS; Esopi D; Yegnasubramanian S; Denmeade SR
    Prostate; 2017 Jun; 77(8):829-837. PubMed ID: 28224650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor suppressive microRNA-1 mediated novel apoptosis pathways through direct inhibition of splicing factor serine/arginine-rich 9 (SRSF9/SRp30c) in bladder cancer.
    Yoshino H; Enokida H; Chiyomaru T; Tatarano S; Hidaka H; Yamasaki T; Gotannda T; Tachiwada T; Nohata N; Yamane T; Seki N; Nakagawa M
    Biochem Biophys Res Commun; 2012 Jan; 417(1):588-93. PubMed ID: 22178073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Down regulation of U2AF1 promotes ARV7 splicing and prostate cancer progression.
    Cao H; Wang D; Gao R; Chen L; Feng Y
    Biochem Biophys Res Commun; 2021 Feb; 541():56-62. PubMed ID: 33477033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen receptor splicing variant 7 (ARv7) promotes DNA damage response in prostate cancer cells.
    Luo H; Liu Y; Li Y; Zhang C; Yu B; Shao C
    FASEB J; 2022 Sep; 36(9):e22495. PubMed ID: 35947121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-naïve prostate cancer cells.
    Lin C; Chou FJ; Lu J; Lin W; Truong M; Tian H; Sun Y; Luo J; Yang R; Niu Y; Nadal R; Antonarakis ES; Cordon-Cardo C; Sahasrabudhe D; Huang CP; Yeh S; Li G; Chang C
    Aging (Albany NY); 2020 Sep; 12(17):17694-17712. PubMed ID: 32920545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resveratrol enhances polyubiquitination-mediated ARV7 degradation in prostate cancer cells.
    Wilson S; Cavero L; Tong D; Liu Q; Geary K; Talamonti N; Xu J; Fu J; Jiang J; Zhang D
    Oncotarget; 2017 Aug; 8(33):54683-54693. PubMed ID: 28903374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isoform-specific Activities of Androgen Receptor and its Splice Variants in Prostate Cancer Cells.
    Nagandla H; Robertson MJ; Putluri V; Putluri N; Coarfa C; Weigel NL
    Endocrinology; 2021 Mar; 162(3):. PubMed ID: 33300995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of Androgen Receptor Variant 7 (
    Hille C; Gorges TM; Riethdorf S; Mazel M; Steuber T; Amsberg GV; König F; Peine S; Alix-Panabières C; Pantel K
    Cells; 2019 Sep; 8(9):. PubMed ID: 31514447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.